Skip to main
AKTS

Aktis Oncology Inc (AKTS)


$0.00

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

Buy AKTS Stock

About Aktis Oncology Inc (AKTS)

Aktis Oncology, Inc. is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company was founded by Todd Foley, Patrick Baeuerle and Brian Goodman in August 2020 and is headquartered in Boston, MA.
Market cap$1.18B
Friday's volume3.12M
Revenue (TTM)
Avg. daily volume1.56M
EBITDA (TTM)
Open$27
Price / earnings ratio
Friday's range$19.33 - $29.16
Debt / equity4.89x
52 week range$0.04 - $29.16
5 year debt / equity7.9x
Beta (LTM)
Interest coverage
Dividend & yield$0.00 (0.00%)
Current ratio15.98x
Ex-dividend date
Next earnings
Dividend payable date

Frequently Asked Questions (FAQ)

As of Jan 10, 2026, the market cap for AKTS stock is $1.18B

The 52-week high for AKTS stock is $29.16. The current AKTS stock price $undefined is 100.00% below its 52-week high

The 52-week low for AKTS stock is $0.04. The current AKTS stock price $undefined has increased 100.00% from its 52-week low

No, the AKTS stock does not pay dividends to its shareholders

How to buy AKTS stock on Public

  1. 1

    Sign up for a brokerage account on Public

    It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.

  2. 2

    Add funds to your Public account

    There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.

  3. 3

    Choose how much you'd like to invest in AKTS stock

    Navigate to the Explore page. Then, type AKTS into the search bar. When you see AKTS stock appear in the results, tap it to open up the purchase screen.

  4. 4

    Manage your investments in one place

    You can find your newly purchased AKTS stock in your portfolio alongside the rest of your stocks, ETFs, crypto, bonds, options, and your high-yield cash account––all in one place on Public.

Aktis Oncology Inc Stock Earnings

The value each AKTS share was expected to gain vs. the value that each AKTS share actually gained.

AKTS (AKTS) reported Q1 2025 earnings per share (EPS) of -$0.04, beating estimates of -$0.11 by 63.64%. In the same quarter last year, AKTS's earnings per share (EPS) was -$0.27. AKTS is expected to release next earnings on , with an earnings per share (EPS) estimate of $0.

Buy AKTS Stock

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.